newsfilter
← Latest News
Business Wire·

AVEO Oncology to Host Key Opinion Leader Webinar on FOTIVDA® (tivozanib) for Relapsed or Refractory Renal Cell Carcinoma

Webinar on Friday, July 16th at 12 p.m. Eastern Time FOTIVDA recently surpassed 300 total commercial prescriptions since its March 22, 2021 launch AVEO Oncology (NASDAQ:AVEO), a commercial and clinical development stage biopharmaceutical company,